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Abstract 1 
Crotoxin (CTX), a heterodimeric phospholipase present in venom of snakes of the genus 2 
Crotalus, has demonstrated a broad spectrum of pharmacological properties, such as 3 
antimicrobial, hemostatic, and antitumoral. However, the precise mechanism of its cytotoxicity 4 
and antitumoral properties remains to be determined. Therefore, in the present study, we 5 
isolated crotoxin (F1 CTX) through two steps DEAE-Sepharose and Heparin-Sepharose FF 6 
chromatography. The C-terminal sequence of the A- and B-chain protein fragment was 7 
determined by LC-MS/MS mass spectrometry, which showed 100% identity to crotoxin 8 
structure. In order to investigate its cytotoxic effects, we demonstrated that the F1 CTX 9 
fraction at 0 to 30 µg/mL concentrations for 72 h presented a heterogeneous response profile 10 
on nine human cancer-derived cell lines from four tumor types (pancreatic, esophagus, 11 
cervical cancer, and glioma). The glioma (GAMG and HCB151) and pancreatic (PSN-1 and 12 
PANC-1) cancer cells showed a higher sensitivity with IC50 of <0.5, 4.1, 0.7 and <0.5 µg/mL, 13 
respectively. Conversely, F1 CTX does not reduce the viability of normal cells. On the other 14 
hand, cervical (SiHa) and esophagus (KYSE270) cancer cell lines presented higher 15 
resistance, with IC50 higher than 30.2 and 8.7 µg/mL, respectively. Moreover, F1 CTX did not 16 
affect cell cycle distribution under the conditions evaluated and seems to be more cytotoxic 17 
than cytostatic. The pro-apoptotic effect of F1 CTX treatment was demonstrated in glioma 18 
(HCB151) cell line. In addition, crotoxin revealed a potential to initiate cell responses such as 19 
DNA damage in glioma (HCB151) and pancreatic cancer by H2AX activity induction. 20 
Conversely, F1 CTX does not reduce the viability of normal cells. Importantly, the comparison 21 
of F1 CTX effect with standard chemotherapeutic agents demonstrated a greater cytotoxic 22 
potential in the majority of tumor types (glioma, pancreatic, and cervical cancer). On the other 23 
hand, F1 CTX was less cytotoxic in esophageal cell lines compared to the gemcitabine agent 24 
used in clinical practice. Therefore, this work showed that F1 CTX has a cytotoxic activity and 25 
pro-apoptotic potential, contributing to the knowledge about the F1 crotoxin properties as well 26 
as its possible use in cancer research, particularly in glioma and pancreatic cancer cell lines. 27 
 28 
Keywords: Crotoxin; snake venom; cytotoxicity; antitumor; glioma; pancreas 29 
 30 
 31 
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1. Introduction  32 
 Snakes of the genus Crotalus produce and secrete a complex of biologically active 33 
substances, among them the phospholipase A2 (PLA2) (Calderon et al., 2014). Snake venom 34 
PLA2 (svPLA2s) comprises a large class of molecules that catalyze the hydrolysis of sn-2 35 
position phospholipids, releasing fatty acids and lysophospholipids. svPLA2s are related to a 36 
broad spectrum of biotechnological activities, including antitumoral, antimicrobial, and 37 
hemostatic. The cytotoxic activity has been suggested to be a result of different cell death 38 
mechanisms, which has been demonstrated in vitro in melanoma, neuroblastoma, and 39 
leukemic cell lines (Baldi et al., 1998; Iglesias et al., 2005; Yan et al., 2007; Rodrigues et al., 40 
2009).  41 
Among the PLA2 isolated from snake venom, crotoxin (CTX), a β-neurotoxin, is a 42 
heterodimeric complex composed of a toxic phospholipase (PLA2) fraction, associated with 43 
the non-enzymatic fraction crotapotin (Sobrinho et al., 2016). Parallel to its toxic effects, 44 
numerous scientific findings have demonstrated the application of CTX in the pharmacological 45 
field, with a broad spectrum of functional properties (Donato et al., 1996; Costa et al., 1997; 46 
Sampaio et al., 2010). CTX cytotoxicity is mediated by specific interactions with cell surface 47 
receptors and associated with transmembrane ligands, which are involved in cell damage 48 
(Krizaj et al., 2000; Montecucco et al., 2008).  49 
The antitumor and antiproliferative activity of CTX in different cancer cell lines including 50 
leukemia, cervix, ovarian, lung, colon, renal, melanoma, and brain has been assessed in in 51 
vitro and in vivo studies. According to these studies, the antiproliferative activity occurs 52 
through apoptotic mechanisms, triggered by changes in mitochondrial membrane potential, 53 
cytochrome C release, and caspase-3 activation (Corin et al., 1993; Newman et al., 1993; 54 
Costa et al., 1998; Brigatte et al., 2016). CTX may also induce cell death by activation of 55 
autophagy mechanisms, which was demonstrated in breast tumor cells (Yan et al., 2007). 56 
Moreover, the ability of CTX to cause cytocidal and memory antitumor immunity in mice have 57 
been determined in lymphoma, adenocarcinoma, human lung squamous cell carcinoma and 58 
esophageal cancer cell lines (Ferguson, Duncan, 2009; Wang  et al., 2012; Qin et val., 2016). 59 
Studies of CTX structure and function have brought relevant information for applications of 60 
this molecule in the treatment of different types of cancer, including phase 1 clinical studies 61 
for the treatment of refractory solid tumors associated with conventional therapies. CTX has 62 
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been investigated for its effective application in malignant tumor treatments, in vivo or in vitro, 63 
alone or in combination with antitumor drugs (Rübsamen et al., 1971; Aird et al., 1989; Rudd 64 
et al., 1994; Donato et al., 1996; Ye et al., 2011; Han et al., 2014; He et al., 2016). However, 65 
new molecular mechanisms must be elucidated to apply the molecule in neoadjuvant 66 
antitumor therapies.  67 
 To better understand the antitumor properties of CTX, in the present study, we isolated 68 
crotoxin from Crotalus durissus terrificus snake venom, evaluated its response profile in nine 69 
human cancer-derived cell lines, and analyzed its cytotoxicity, antiproliferative and pro-70 
apoptotic potential. 71 
  72 
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2. Materials and Methods  73 
2.1. Reagents and venom  74 
 The yellowish Crotalus durissus terrificus venom was purchased from Koemitã Me 75 
(Mococa, SP, Brazil). Sepharose G-75 and Heparin-Sepharose FF were purchased from 76 
Amersham Life Science, Inc. All of the other reagents used in this study were of analytical 77 
grade and purchased from Sigma Chem. Co, Merck and/or Synapse Biotechnology.  78 
 79 
2.2. Purification of Crotoxin (CTX)  80 
 C. durissus terrificus crude venom (0.5 g) was applied to a DEAE-cellulose column, 81 
which had previously been equilibrated with 0.05 M Tris-HCl, pH 7.5 (buffer A), and the 82 
protein was eluted with 0.05 M Tris-HCl, pH 7.5 in a linear gradient of NaCl (0–1 M); 2 mL 83 
fractions were collected. The eluted fraction with crotoxin activity was concentrated in an 84 
ALPHA 2-4 LD plus Freeze-Dryer. Of the F4 CTX fraction, 50 mg were applied to the Heparin-85 
Sepharose FF column (HiTrap, heparin (HP), 5 mL), which had previously been equilibrated 86 
with 0.01 M sodium phosphate, pH 7.0. The protein was eluted in linear gradient of NaCl (0–87 
1.5 M) at a flow rate of 2.5 mL/min, and 3 mL fractions were collected. The F1 CTX fraction 88 
was pooled and functional and biochemical characteristics were assessed. Chromatography 89 
was performed using the ÄKTAprime and liquid chromatography system (GE Healthcare). 90 
Next, F1 CTX was subjected to identification and cytotoxic effects evaluation. All purification 91 
and isolation procedures were performed at room temperature.  92 
 93 
2.3. Identification of Crotoxin: internal peptide fragments 94 
 The purity of F1 CTX was determined by 15% (w/v) SDS-PAGE in a Tris-glycine buffer 95 
of pH 8.3, for 120 min at 20 mA/100 V. The molecular mass was measured using the 96 
Carestream Molecular Imaging Software (Carestream Health, Inc., 1994-2011) and at 10–260 97 
kDa molecular weight calibration standards (EspectraTM Multicolor Broad Range).  98 
 The identification of crotoxin was determined by mass spectrometry. A coomassie 99 
brilliant blue-stained crotamine band (approximately 2 µg/spot) was cut out of the 100 
polyacrylamide gel (13%) and digested “in-gel” for peptide mass fingerprinting and for internal 101 
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sequence determination. Five micrograms of isolated F1 CTX were reduced in 10 mM DTT, 102 
alkylated in 50 mM of iodoacetamide, and then trypsinized in 20 ng/µL trypsin after gel 103 
electrophoresis, according to the protocol reported by Shevchenko et al. (1996), with some 104 
modifications. Tryptic fragments of the peptide were scored by the bond cleavage, and 105 
charges on the C-terminus (a ions) and N-terminus (b ions) were generated. Peptide 106 
identification was performed in a liquid chromatography-tandem mass spectrometer using a 107 
C18 nanocolumn (LC-MS / MS Q-TOF PREMIERTM). The resulting spectra were analyzed 108 
using Mascot (Matrix Science) in the NCBI protein databases, with carbamidomethylation as 109 
the fixed modification. The similarity between peptide sequences was assessed with BLAST. 110 
 111 
2.4. Cytotoxic activity evaluation 112 
2.4.1. Cell lines and cell culture  113 
 Nine immortalized human cancer-derived cell lines were used in the cytotoxicity 114 
assays, comprising brain (glioma), pancreatic, cervical, and esophageal tumor models. In 115 
addition, immortalized keratinocytes (hacat cells - ThermoFisher) and murine fibroblasts 116 
(NIH/3T3 (ATCC® CRL-1658™) were used as non-cancer cells. Cells were cultivated in 117 
Dulbecco's modified Eagle's medium (DMEM 1X, high glucose; Gibco, Invitrogen) or Le 118 
Roswell Park Memorial Institute medium (RPMI-1640 1X, Gibco, Invitrogen) supplemented 119 
with 10% fetal bovine serum (FBS) (Gibco, Invitrogen) and 1% penicillin/streptomycin solution 120 
(Gibco, Invitrogen), at 37°C and 5% CO 2, as previously reported (Silva-Oliveira et al., 2016; 121 
Silva et al., 2018). Authentication of cancer cell lines was conducted by the Diagnostic 122 
Laboratory of Barretos Cancer Hospital (São Paulo, Brazil) as reported (Dirks et al., 2005; 123 
Silva-Oliveira et al., 2016; Teixeira et al., 20016). The cell lines identities were confirmed by 124 
genotyping, with the exception of U373, which was shown to be a subclone of the U251 125 
lineage. In addition, a primary tumor culture (HCB151) was obtained from a glioblastoma 126 
biopsy and provided by the Department of Neurosurgery of the Barretos Cancer Hospital 127 
(Cruvinel-Carloni et al., 2017).  128 
 129 
2.4.2. Cell viability assay  130 
 The cytotoxic effect of F1 CTX or standard chemotherapeutic agents (paclitaxel (Sigma 131 
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- T7402), gemcitabine hydrochloride (Sigma - G6423), temozolomide (Sigma - T2577) and 132 
cisplatin (Sigma - 479306) was analyzed by the MTS assay [3-(4,5-dimethylthiazol-2-yl)-5-(3-133 
carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium], (Cell Titer 96 Aqueous cell 134 
proliferation assay-MTS, PROMEGA). Cell viability was determined by the survival rate, after 135 
incubation with the MTS reagent (2h; 37°C, 5% CO 2) in the cell culture (until a maximum 5 x 136 
103 cells/well), which was treated with increasing concentrations of F1 CTX (0.5–30 µg/mL or   137 
standard chemotherapeutic agents (0.5–150 µg/mL); 72h), and compared to the control group 138 
(1% DMSO, final concentration). The absorbance was measured spectrophotometrically 139 
(λ490nm) in an automatic microplate reader system (Varioskan, Thermo). The results obtained 140 
in the cell viability assay with the different concentrations of F1 CTX or standard 141 
chemotherapeutic agents were converted to percent viability in relation to the control (1% 142 
DMSO) ± SD. All the assays were done in triplicate and repeated at least three times The 143 
half-maximal inhibitory concentration (IC50) was calculated by non-linear regression analysis 144 
using GraphPad PRISM 5.1 (GraphPad Software, La Jolla California USA), as previously 145 
reported (Teixeira et al., 2016).  146 
 147 
2.4.4. Effects of CTX on cell cycle and apoptosis  148 
  The effects of F1 CTX on cell cycle and apoptosis was evaluated in HCB 151 (drug-149 
sensitive) and SiHa (drug-resistant) cell lines (1×106 cells/well) using a concentration 150 
equivalent to IC50 value of each cell line for 24 h. For cell cycle analysis, cells were examined 151 
using PI stain to determine DNA content and analyzed using Cycle Test kit (BD Biosciences) 152 
following the manufacturer’s recommended protocol. Apoptosis assays were performed using 153 
the Annexin V-FITC kit (BD Biosciences) according to the manufacturer’s recommendations. 154 
The distribution profile (G1, S, and G2/M) and the percentage of apoptotic cells were 155 
characterized by flow cytometry using the BD FACSCanto II reagent kit (BD Biosciences) and 156 
analyzed with BD FACSDiva software (BD Biosciences). 157 
 158 
2.4.5. Molecular Analysis by Western Blot   159 
In a direct immunoblot experiment, HCB151, PANC-1, and SiHa cell lines (1×106 160 
cells/well) were exposed to IC50 concentration values of F1 CTX for 24h. Protein samples, 161 
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previously obtained by cell lysis, were separated and analyzed by SDS-PAGE and transferred 162 
to a Hybond-C nitrocellulose membrane (Amersham Biosciences, Little Chalfont, UK) using a 163 
mini turbo transfer system (Trans-Blot® BioRad) as reported (Plescia et al., 2005). 164 
Membranes were blocked for 1h (5% milk powder in TBS/0.1% Tween (TBS-T; pH = 7.6) and 165 
incubated overnight (4°C) with the primary antibodi es (p-H2AX, p-AKT, AKT, p-P44/42 166 
(MAPK- ERK1/2), p44/42, p21, and β-tubulin) diluted 1:1000 (Cell Signaling Technology). The 167 
washed membranes were incubated with the secondary antibody and coupled to horseradish 168 
peroxidase, 1:5000 (Cell Signaling Technology). β-tubulin was used as loading control. 169 
Protein bands were determined by chemiluminescence (ECL Western Blot Detection 170 
Reagents, RPN2109, GE Healthcare) and signal intensity was assessed with the 171 
ImageQuant™ LAS 4000 mini photographic documentation system (GE Healthcare). The 172 
densitometry analysis of immunoblots was performed with the Image J software (version 1.41; 173 
National Institutes of Health). 174 
 175 
5. Statistical analysis 176 
 Student's t-test was used to compare each experimental group with the control group. 177 
The p value <0.05 indicated a significant difference between the samples. Graphs and 178 
statistical analysis were performed in GraphPad Prism 5.1 software. 179 
  180 
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3. Results 181 
3.1. Purification and identification of CTX  182 
 The F1 CTX molecule was isolated in two chromatographic steps: first, by exclusion 183 
chromatography using a DEAE-cellulose column (Figure 1A), and second, by bioaffinity 184 
chromatography in a Heparin-Sepharose FF column (Figure 1B). The degree of purity was 185 
assessed by SDS-PAGE revealing a dimeric, low molecular weight protein consisting of two 186 
subunits with apparent molecular weight between 14–15 kDa (Figure 1C). Further peptide 187 
fragments identified in the mass fingerprinting corresponding to MS/MS fragmentation of three 188 
internal peptide fragments (Chain A) and four fragments (Chain B), confirmed the molecular 189 
identity of crotoxin (Figure 1D). 190 
Fig. 1 191 
 192 
193 
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3.2. CTX cytotoxic profile  194 
 CTX cytotoxic potential was determined by MTS assays in brain (glioma), pancreatic, 195 
cervical, and esophageal cancer cells at different concentrations (0 to 30 µg/mL). The authors 196 
suggested F1 CTX might be a selective anti-cancer agent, discriminating between normal and 197 
tumor cells. The dose-response curves showed that cell lines exhibited a heterogeneous 198 
cytotoxic profile in response to F1 CTX (Figure 2 and table 1). The mean IC50 was 8.6 µg/mL 199 
and varied significantly between cell lines, with differences of more than sixty-fold (IC50 range: 200 
<0.5 – >30 µg/mL) (Table 1). The KYSE 30 (esophageal), GAMG, HCB151 (glioma), PSN-1, 201 
PANC-1 (pancreatic), and HeLa (cervical) tumor cells showed higher sensitivity, with IC50 of 202 
1.0, <0.5, 4.1, 0.7, <0.5, and 2.4 µg/mL, respectively (Figure 2 A, C, E, F, G and H). On the 203 
other hand, the KYSE 270 (esophageal), U373 (glioma), and SiHa (cervical) cells exhibited 204 
higher resistance, with IC50 of 8.7, 30.2 and >30.0 µg/mL, respectively (Figure 2 B, D, and I). 205 
In contrast, identical concentrations of F1 CTX did not reduce the viability of normal human 206 
keratinocytes (HaCaT) or mouse fibroblasts (3T3) cell lines on the same conditions of assay 207 
(Figure 2 J and K). 208 
Additionally, we compared the F1 CTX cytotoxic potential with standard 209 
chemotherapeutic agents for glioma, pancreatic, esophagus, and cervical cancer. CTX 210 
treatment was more cytotoxic in the majority of tumor types (glioma, pancreatic, and cervical 211 
cancer). In contrast, F1 CTX was less cytotoxic in esophageal cell lines compared to the 212 
gemcitabine agent used in clinical practice (Table 1). 213 
 214 
 215 
 216 
 217 
 218 
 219 
 220 
 221 
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Fig. 2 223 
 224 
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3.3. CTX antiproliferative and pro-apoptotic effects  259 
Since we observed a cytotoxic effect of F1 CTX in cancer cells, we further determined 260 
its effect on cell cycle distribution and cell death using flow cytometric analysis. As shown in 261 
Figure 3 (A,B,C,D), no significant effect was observed in drug-sensitive (HCB151 – 4.1µg/mL) 262 
or drug-resistant cells (SiHa -30 µg/mL) after toxin treatment, suggesting that CTX at 263 
concentrations used has no interference on cell cycle distribution under the conditions 264 
evaluated (Figure 3 B.D). Next, we examined the apoptosis-inducing effect of F1 CTX. The 265 
basal population of early and late apoptotic cells in the untreated cultures was 0.6% and 0.1% 266 
(HCB 151) and 4.8% and 7.2% (SiHa). However, when cancer cells were treated with F1 CTX 267 
at IC50 value for 24 h, the apoptotic cells (early + late apoptosis) increased by 13.2% and 268 
11.0% (HCB 151) compared to the control cells (Figure 4 A,B). No significant effect was 269 
observed in SiHa cell (Figure 4 C,D).  270 
 271 
 272 
 273 
 274 
 275 
 276 
 277 
 278 
 279 
 280 
 281 
 282 
 283 
 284 
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 286 
Fig. 3 287 
 288 
 289 
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 294 
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 297 
 298 
 299 
Fig. 4 300 
 301 
3.4. Effects of CTX on cell signaling 302 
To better explore the underlying mechanisms of F1 CTX, we assessed the expression 303 
of the main proteins related to proliferation/survival and DNA damage mechanism induced by 304 
molecule. The protein expressions after F1 CTX treatment in cancer cells (HCB151, PANC-1 305 
and SiHa) were quantified relative to untreated control cells. As shown in Figure 5, we 306 
observed an increase of H2AX phosphorylation, an important marker of DNA damage in 307 
HCB151 cells; it was remarkably upregulated in PANC-1 (Figure 5 A, B). p21 expression, an 308 
important cell cycle regulator, did not change in any cell lines corroborating the data obtained 309 
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through flow cytometry. In addition, no change in response to CTX was observed for p-AKT, 310 
AKT (pan), pP42/44 and P42/44 in the three cell lines evaluated (Figure 5 A) 311 
 312 
 313 
Fig. 5 314 
 315 
 316 
 317 
 318 
 319 
 320 
 321 
 322 
 323 
 324 
 325 
 326 
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 328 
4. Discussion  329 
In this study, crotoxin, a phospholipase A2 from Crotalus durissus terrificus venom was 330 
purified to homogeneity in a two-step procedure using ion exchange chromatography followed 331 
Heparin Sepharose affinity chromatographic. Due to its unique structure and surface charge 332 
distribution, the heparin matrix was able to interact strongly with some components in the 333 
crude venom, whereas crotoxin (F1 CTX) showed a low affinity to the column (Figure 1). 334 
Crotoxin is a heterodimeric complex consisting of a weakly basic, toxic, and non-hemolytic 335 
PLA2 (B subunit or crotoxin CB) and an acid, non-toxic, non-enzymatic and hemolytic 336 
component known as crotapotin (A subunit or crotoxin CA) that potentiates the toxicity of the 337 
molecule, acting as a chaperone protein (Neumann, Habermann, 1955; Fraenkel-Conrat, 338 
Singer, 1956; Fraenkel-Conrat, 1971; Marlas, Bon, 1982; Radvanyl, Bon, 1982; Andrião-339 
Escarso et al., 2002; Faure, Saul, 2012). The subunit CB or PLA2 presents about 14 kDa, 340 
isoelectric point 9.7, consisting of a single polypeptide chain of 122 amino acid residues, 341 
stabilized by seven disulfide bridges (Aird et al., 1989; Faure, Saul, 2012). The CA subunit 342 
(crotapotin) has a molecular weight of 8.9 kDa, isoelectric point of 3.4, and has no enzymatic 343 
or toxic activities (Rübsamen et al., 1971; Bon et al., 1989). Faure et al., (2012) have been 344 
demonstrated that this subunit comprises three covalently linked polypeptide chains (α, 39 345 
residues, β, 35 residues and γ, 14 residues). Our results showed peptide fragments that were 346 
generated by mass fingerprinting and confirmed the identity of both A and B subunits of 347 
crotoxin (Figure 1). Some authors suggest that combinations of these subunit complexes or 348 
post-translational modifications originate the different described isoforms of CTX (Faure et al., 349 
1988; Faure et al., 1991; Faure et al., 1993). 350 
 We first investigated the cytotoxic profile of F1 CTX action against four different types 351 
of solid tumor cell lines. In our studies, the lowest IC50 value (>0.5 µg/mL) was found for the 352 
pancreatic tumor cell line (PANC-1) and glioma (GAMG), which demonstrated greater 353 
sensitivity. Notably, F1 CTX also promoted cytotoxicity in HCB151, PSN-1, PANC-1, HeLa, 354 
and KYSE 30 cell lines. In contrast, purified CTX exerted significantly lower cytotoxicity in the 355 
esophageal tumor cell line (KYSE 270), presenting an IC50=8.7 µg/mL. In the same way, we 356 
observed a greater resistance for glioma (U373, IC50=30.1 µg/mL) and cervical cancer (SiHa, 357 
IC50>30 µg/mL) cells. Our study was performed in according to the criterion adopted by 358 
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American National Cancer Institute (NCI) to consider an extract promising for preclinical 359 
studies when IC50 values presented are lower than 30 µg/mL for 72 h (http://www.cancer.gov) 360 
(Chou, Talalay, 1984; Suffness, Pezzuto, 1990; Talib, Mahasneh, 2010; Kuete et al., 2013; 361 
Trendowski, 2015). 362 
Thus, our results demonstrated that the isolated CTX presented cytotoxic effects on 363 
different tumor cell lines with a heterogeneous response profile. One of the main objectives of 364 
targeted cancer therapy is to selectively eliminate tumor cells while sparing normal tissues. 365 
Although, we had no normal counterpart available for many of the tissues evaluated, we used 366 
mouse fibroblasts and human normal keratinocytes, which are strongly affected by anti-367 
neoplastic chemotherapies (Plescia et al., 2005) to compare cytotoxic potential of CTX. We 368 
demonstrated that CTX had no effect on viability of normal human keratinocytes (HaCaT) or 369 
mouse fibroblasts (3T3) cell lines at concentrations tested. Ferguson and Duncan (2009) 370 
reported significant cytotoxic activity with Crotalus durissus terrificus PLA2 on colon 371 
adenocarcinoma (HT29), melanoma (B16F10), and breast adenocarcinoma (MCF-7) cells 372 
with an IC50 of 40, 108.3, and 308.6 µg/mL respectively. In order to reduce the toxicity of the 373 
molecule, these authors conjugated PLA2 with dextrin by the polymer masked-unmasked 374 
protein therapy method and showed that the conjugate presented a marked reduction in 375 
hemolytic activity and greater cellular cytotoxicity, but with an IC50 value of 16.3 µg/mL for 376 
HT29, and 62.9 µg/mL for MCF-7. In a previous study, Rudd et al. (1994) highlighted that 377 
crotoxin displays low toxicity in normal cells, suggesting its selective toxicity to tumors.  378 
The ant proliferative and cytotoxic activities of CTX have been demonstrated through 379 
cell cycle arrest and pro-apoptotic mechanisms (Costa et al., 1998; Ferguson, Duncan, 2009; 380 
Wang et al., 2012; Han et al., 2014). However, we did not observe interference on cell cycle 381 
distribution under the conditions evaluated. This finding seems to be in disagreement with 382 
studies with lung adenocarcinoma (A-549), esophagus (ECA-109), and lung carcinoma (SK-383 
MES-1) lines (Rudd et al., 1994; He et al, 2013; Han et al., 2014), which demonstrated growth 384 
inhibitory effects by cell cycle arrest. To further explore the role of CTX in cell death 385 
mechanism, we investigated its effect in protein expression related to DNA damage, 386 
proliferation/survival and cell death. The pancreatic (PANC-1) cell line exhibited a significant 387 
upregulation of H2AX activity, suggesting possible DNA damage effect (Ivashkevich et al., 388 
2012; Siddiqui et al., 2015; Ji et al., 2017). Likewise, the glioma cell line (HCB 151) showed a 389 
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slight increase of H2AX activity and increased percentage of apoptotic cells (early + late 390 
apoptosis) after CTX treatment evaluated by flow cytometer. Therefore, CTX exposure 391 
induced alterations in different pathways involved in DNA damage and mortality. Studies have 392 
shown that the molecular cytotoxic mechanisms of PLA2 involve the regulation of different 393 
signaling pathways, and that this effect is dependent of enzymatic activity. These studies 394 
revealed that the dissociation of the complex and the enzymatic activity are necessary for 395 
cytotoxicity, because when the catalytic activity of the complex or the PLA2 subunit is 396 
alkylated, cytotoxic activity is lost (Corin et al., 1993; Soares, Giglio, 2003; Marchi-Salvador et 397 
al., 2008; Sobrinho et al., 2016).  398 
The pro-apoptotic effect of CTX has been shown to trigger changes in mitochondrial 399 
membrane potential, cytochrome C release, and caspase-3 activation (Donato et al., 1996; 400 
Costa et al., 1997; Sampaio et al., 2010; Sobrinho et al., 2016). It has also been 401 
demonstrated that CTX induces cell death by autophagy mechanisms in breast and lung 402 
cancer cells (Yan et al., 2007; Han et al., 2014) and inhibits the growth of Eca-109 cells in 403 
vitro via apoptosis induction and G1 phase arrest (Ye et al., 2011). Interestingly, Wang et al 404 
(2012) showed that the combination of CTX with tyrosine kinase inhibitor gefitinib (Iressa) 405 
significantly enhanced the antitumor activity of gefitinib and caused increased damage to 406 
blood vessels and reduced tumor size in vivo. These studies suggest that CTX cell 407 
cytotoxicity depends on tumor type, which may indicate distinct mechanisms of action. 408 
In addition, we compared the effect of CTX with standard chemotherapeutic agents for 409 
glioma, pancreatic, esophagus, and cervical cancer. Our results demonstrated that crotoxin 410 
treatment was more cytotoxic than their corresponding chemotherapeutics in the majority of 411 
tumor types (glioma, pancreatic, and cervical cancer). Once the synergy (chemo-412 
sensitization) of known and new compounds are of major interest, this study opens new 413 
perspectives for classical chemotherapy. However, the response level seen in practice is still 414 
suboptimal and there is an urgent need for improvement (Wiedmann, Mossner, 2013; 415 
Voutsadakis, 2011). Our results provide insights for further studies with CTX as an interesting 416 
antineoplastic agent in glioma and pancreas cancer lines.  417 
 418 
5. Conclusions  419 
 In conclusion, F1 CTX fraction from Crotalus durissus terrificus was purified with 420 
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electrophoretic homogeneity. Purified hetero-dimer enzymes showed significant cytotoxicity 421 
exhibiting substantial activity against several cancer cell lines, while normal cell lines were 422 
not affected. Mechanistically, F1 CTX promotes pro-apoptotic effects and induces a potential 423 
DNA damage on pancreatic (PANC-1) and glioma (HCB151) cell lines, revealed through the 424 
increase in H2AX activity. Interestingly, F1 CTX demonstrated a greater cytotoxic potential 425 
than the specific standard chemotherapeutic agents used in clinical practice in the majority of 426 
tumor types (glioma, pancreatic, and cervical cancer). These results add to the functional 427 
knowledge database on crotoxin, and provide new insights into the development of antitumor 428 
therapy. 429 
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 680 
Figure legends 681 
Figure 1. Purification and isolation of Crotoxin (CTX). (A) Ion exchange chromatography 682 
of the crude venom of Crotalus durissus terrificus on DEAE-c column, which had been 683 
previously equilibrated in 0.05 M Tris-HCl, pH 7.5, and eluted in increasing gradient of NaCl 684 
(0.1 M) in 0.05 M Tris-HCl, pH 7.5. Fractions of 2 mL were collected and analyzed in a 685 
spectrophotometer (λ280nm). (B) Heparin-Sepharose FF (HiTrap, heparin (HP), 5 mL) column 686 
of the F4 CTX (50 mg) previously equilibrated with 0.01 M sodium phosphate, pH 7.0 and 687 
eluted in linear gradient of NaCl (0–1.5 M) at a flow rate of 2.5 mL/ min. Fractions of 3 mL 688 
were collected and analyzed in a spectrophotometer (λ280nm). (C) SDS-PAGE using a 13% 689 
acrylamide-bisacrylamide (w/v) gel in Tris-glycine buffer, pH 8.3. Lane 1: molecular weight 690 
markers; lane 2: crude venom (CV) (10 µg); and Lane 3: CTX (10 µg). (D) Mass spectrometry 691 
of CTX. Five micrograms of isolated CTX were reduced in 10 mM DTT, alkylated in 50 mM 692 
iodoacetamide, and digested with 20 ng/µL of trypsin. Protein identification was performed in 693 
a mass spectrometer coupled to an HPLC using a C18 nanocolumn. The resulting spectra 694 
were analyzed using Mascot (Matrix 5 Science) in the NCBI nr protein databases, with 695 
carbamidomethylation as the fixed modification. Similar peptide sequences were identified 696 
using BLAST. Peptide fragments are observed in b ions (N-terminus), and y ions (C-697 
terminus). a∗, b∗, and y∗ represent ion fragments of RKNQ that have lost ammonia (-17 Da). b° 698 
represent ion fragments of STED that have lost water (-18 Da). 699 
 700 
Figure 2. Effect of crotoxin (CTX) on cell viability of normal and human cancer-derived 701 
cell lines. Viability of tumor cells was determined by the MTS assay after incubation with 702 
different concentrations of crotoxin (0.5–30 µg/mL) for 72 h. (A and B) Esophageal cancer 703 
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cells (Kyse 270 and Kyse 30). (C-E) Glioma cells (GAMG, HCB 151 and U373). (F and G) 704 
Pancreatic cancer cells (PSN-1 and PANC-1). (H-I) Cervical cancer cells (HeLa and SiHa). (J-705 
K) Normal human keratinocytes (HaCaT) and mouse fibroblasts (3T3) respectively. Results 706 
from three replicates are reported as the mean percentage of viable cells ± SD compared to 707 
control (DMSO - considered as 100% viability). The results of tree replicates were expressed 708 
as the mean percentage ±SD of viable cells relatively to the control (considered as 100% 709 
viability). The differences between the means and the significance of the treatments were 710 
analyzed with GraphPad Prism (Version 6.01) using Student’s t-test. *P<0.05, **P<0.01, 711 
***P<0.001.  712 
 713 
Figure 3. Effect of crotoxin (CTX) on cell cycle distribuition. Representative cell cycle 714 
analysis by flow cytometry of (A) HCB151 and (C) SiHa cells, in absence (Control - 1% 715 
DMSO) or presence of FI CTX (HCB 151, IC50 = 4.1 µg/mL, SiHa, IC50 = 30 µg/mL), after 24 716 
h. Summary of percentage of cells in each phase of the cell cycle are indicated by bars as the 717 
mean ± SD and differences with p <0.005 in the Student's t-test (**).n.s. means non-718 
significant. The X-axis represents the channel number (relative DNA content/cell). The Y-axis 719 
represents the number of cells/channel.  720 
 721 
Figure 4. Effect of crotoxin (CTX) on cell death mechanisms. After 24 h treatment with 722 
crotoxin, (A) HCB151 and (C) SiHa cells were fixed, stained with annexin V / PI, and analyzed 723 
by flow cytometry using FACScan. The data represent three independent experiments. Non-724 
treated CTR: DMSO (1%) and crotoxin-treated cells (HCB151, IC50 = 4.1 µg/mL; SiHa, IC50 = 725 
30 µg/mL). (B-D) Bars represent the percentage of apoptotic cells as the mean ± SD and 726 
differences with p <0.005 in the Student's t-test (**).n.s. non-significant. 727 
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 728 
 729 
Figure 5. Effect of crotoxin (CTX) on protein profile of human cancer-derived cell lines. 730 
(A) Drug-sensitive (HCB151 and PANC-1) and drug-resistant (SiHa) cells were incubated with 731 
crotoxin at the IC50 of 4.1 µg/µL, 0.5 µg/µL and 30 µg/µL respectively for 24 h. DMSO (1%) 732 
was used as negative control. The cell extracts were subjected to Western blotting to analyze 733 
the protein expression levels. Β-tubulin was used as internal control. (B) Densitometry with 734 
levels of protein activity. Proteins were quantified by the ImageJ program. The asterisks (**) 735 
indicate statistical significance (p <0.005) between control and experimental group in the 736 
Student's t test. n.s. non-significant. 737 
 738 
Tables 739 
 740 
Table 1 The CTX, temozolomide, gemcitabine, paclitaxel, and cisplatin half-maximal inhibitory 741 
concentration (IC50) against the human cancer-derived cell lines. 742 
 743 
 744 
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Table 1 The F1 CTX, temozolomide, gemcitabine, paclitaxel, and cisplatin half-maximal inhibitory concentration (IC50) against 
human cancer-derived cell lines. 
 
 
Cell line 
F1 CTX 
   Mean IC50 
±S.D 
(μg/mL) 
 
Temozolomide 
Mean IC
50
± S.D 
(μg/mL) 
 
Gemcitabine 
Mean IC
50
 ± S.D 
(μg/mL) 
Paclitaxel 
Mean IC
50
 ± S.D 
(μg/mL) 
Cisplatin 
   Mean IC
50
 ± S.D 
(μg/mL) 
 
 
Origin 
 
Organism 
 
 
Tissue 
 
Culture conditions 
 
GAMG < 0.5 18.8± 2.0 ND ND ND Glioblastoma  Human Brain DMEM + 10% FBS + 1% P/S 
U373 30.1±1.5 105.7± 1.5 ND ND ND Glioblastoma 
astrocytoma 
Human Brain DMEM + 10% FBS + 1% P/S 
HCB151 4.1±3.8 17.5±0.5 ND ND ND Primary glioma Human Brain DMEM + 10% FBS + 1% P/S 
PANC-1 < 0.5 ND 8.8±2.6 ND ND Pancreatic cancer Human Pancreas DMEM + 10% FBS + 1% P/S 
PSN-1 0.69±0.08 ND 1.4±0.02 ND ND Pancreatic cancer Human Pancreas DMEM + 10% FBS + 1% P/S 
KYSE30 0.9±1.7 ND ND 0.005± 0.003 ND Squamous cell 
carcinoma 
Human esophagus RPMI 1640 + 10% FBS + 1% 
P/S 
KYSE270 8.7±1.4 ND ND 0.006±0.002 ND Squamous cell 
carcinoma 
Human esophagus RPMI 1640 + 10% FBS + 1% 
P/S 
HeLa 2.4±1.1 ND ND ND 6.3±1.8 Cervix carcinoma Human Cervix DMEM + 10% FBS + 1% P/S 
SiHa >30 ND ND ND 14.9±3.6 Squamous Cell 
Carcinoma 
Human Cervix DMEM + 10% FBS + 1% P/S 
NHI/3T3 >30 ND ND ND ND  
Fibroblast 
Mouse Embryo DMEM + 10% FBS + 1% P/S 
HaCat >30 ND ND ND ND Normal 
Keratinocytes 
Human Skin DMEM + 10% FBS + 1% P/S 
 
FBS. Fetal Bovine Serum; P/S Penicillin/Streptomycin solution; ND. Not done. All the assays were done in triplicate and repeated 
at least three times.  
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Highlights 
Crotoxin demonstrated cytotoxic effect on different tumor cell lines. 
The molecule had a heterogeneous cytotoxic effect on the different tumor lines. 
The glioma and pancreatic cancer cells showed a higher sensitivity. 
Cervical and esophagus cancer cell lines presented higher resistance. 
